PubMed Health⌕ Search

Biomedical subjects

F Pecchio

Publications and source records attributed to F Pecchio.

At least 37 records · Page 2Linked to original sources
PubMed1988

TA 4-SCC versus CEA sensitivity for lung cancer.

The sensitivity of a new tumor marker, TA 4-SCC, for lung tumors is examined and compared with the performance of the already established CEA. TA 4-SCC sensitivity is only moderate (30%), and it presents no significant differences among the various histologic types of lung cancer. In addition, unlike CEA, TA 4-SCC is present in large amounts in the serum of many stage I and II patients. In fact, its sensitivity in still curatively operable tumors reaches 30% compared to 10% with CEA.

Adenocarcinoma↗
PubMed1988

[Ca 19-9 and Ca 50 in the diagnosis of bronchial carcinoma: comparison with CEA].

The search for early tumour markers has brought to light CA 19-9 and CA 50, glycoproteins recognised by monoclonal antibodies. Since these markers are mainly used on the digestive tract it was thought useful to investigate their value in the diagnosis of lung cancer which is only rarely identified by markers in its early stages. The two markers were compared with the better known CEA on 43 healthy volunteers, 42 patients with chronic lung conditions, 26 people with localised non-neoplastic lung shadows and 255 patients with staged and histologically identified lung tumours. The results obtained reveal the two markers to be of little use in lung cancer since though satisfactorily specific they are not at all sensitive even in the advanced stages of the disease. They could however be used to advise against surgery if positive.

Adenocarcinoma↗
PubMed1988

[Determination of serum neuron-specific enolase in bronchial tumors of neuroendocrine origin].

Neurone-specific enolase, a serum marker of neuroendocrine tumours has been determined in small-cell anaplastic bronchial carcinomas, in typical and atypical carcinoid. The marker presents good sensitivity in small-cell tumours and in atypical carcinoids, while blood levels are within normal limits in cases of typical carcinoid. The low serum levels of neurone-specific enolase found in typical carcinoid suggest a failure of the enzyme to express itself in the circulation owing to the poor or lack of cellular necrosis.

Biomarkers, Tumor↗
PubMed1988

[Relations between markers and immunological status in surgical patients. Tumor markers and immunity in surgery].

The correlation between the immunological status of surgical patients and cancer is examined. 52 patients with gastric and colonic cancer were studied. On the basis of the immunological results of skin tests these were subdivided into non-reactive and reactive. The two groups were statistically compared in relation to cancer stage and blood concentrations of 4 markers: CEA, Ca 19-9, Ca-50, T.A.T.I. The first data show that anergic patients are older to a statistically significant degree; the second that there are no significant differences between the two groups as regards cancer stage. The third data show a difference between the two groups in relation to two of the four markers; anergic patients have a statistically significant higher blood concentration of CEA and T.A.T.I. This is rather interesting, since the literature offers no specific studies on the correlation between the patient's immunological status and tumour marker concentration. Therefore, in clinical practice, the high concentrations of these markers, could reveal, as well as the presence of cancer an endangered immunologic status.

Adenocarcinoma↗
PubMed1987

[Usefulness of the determination of CEA and Ca 19-9 in the diagnosis and staging of bronchial carcinoma].

The value of CEA and Ca 19-9 assays in the diagnosis and staging of lung cancer is examined. The particular sensitivity of CEA especially in extensive or metastasised tumours is demonstrated. The minimal sensitivity of Ca 19-9 is pointed out but also its absolute specificity in high risk control groups (smokers and BPCO). It is therefore concluded that Ca 19-9 might be used together with CEA in the diagnosis and staging of lung cancer.

Antigens, Neoplasm↗
PubMed1987

[CA-50: evaluation of a new tumor marker in the diagnosis of neoplastic pathologies of the gastrointestinal tract].

In order to assess the diagnostic value of CA-50, a new tumour marker, a series of 226 patients with gastroenteric tumours, 152 healthy controls and 175 patients with benign gastrointestinal pathologies, was examined. CEA, CA 19-9, Alphafetoprotein and CA-50 were assayed in all subjects and the results subjected to statistical analysis in order to discover the sensitivity, specificity and diagnostic value of the new marker. Studies conducted to date indicate that CA-50 assays may be of some value in the diagnosis of pancreatic and liver tumours but are no improvement on existing markers in clinical use, for the diagnosis of gastroenteric tumours. Indeed CA-50 gives a very large number of false positive especially in cirrhosis and to a lesser extent in chronic pancreatitis.

Antigens, Neoplasm↗
PubMed1987

[Diagnostic contribution of carcinoembryonic antigen (CEA) in the pleural fluid and serum of patients with metastatic pleural effusion caused by neoplasm of the breast].

The problem of the diagnosis of pleural exudates in breast cancer is examined. It is pointed out that cytology is very little help and it is suggested that carcinoembryonic antigen could be used for assays of the serum and pleural fluid given its high sensitivity even when the cytological examination is negative.

Breast Neoplasms↗
PubMed1986

[Usefulness of the determination of CA 19-9 in the follow-up of patients with gastroenteric neoplasms in comparison to CEA].

28 cases of carcinoma of the digestive tract were studied in order to assess the value of assaying a new tumour marker (CA 19-9) on monitoring the postoperative course of neoplasia. CEA, a tumour antigen of more certain dependability was assayed at the same time. In the case series examined it was found useful to monitor both antigens since although CA 19-9 is less sensitive then CEA in cancers of the large intestine, it is more sensitive in carcinomas of the stomach and pancreas. These early data will have to be confirmed on larger samples but in general terms they do indicate the value of the combined monitoring of this new antigen and CEA in the follow-up of patients given surgery for carcinoma of the digestive tract.

Antigens, Neoplasm↗
PubMed1986

[pH measurement in the diagnosis of pleural exudates].

The diagnostic accuracy of pH measurement of various types of pleural exudate is examined. Despite the limitations of this examination it is easy and quick to perform and offers an undeniable diagnostic validity especially in the case of pleural transudates or malignant effusions.

Adult↗
PubMed1986

[Tumor-associated markers in malignant lung neoplasms].

The usefulness of assaying tumoral markers in lung cancers is examined. 63 patients (56 men and 7 women) suffering from various types of malignant lung cancers were examined and compared with 44 patients hospitalised for benign lung complaints. The markers used were: CEA, Ferritin, GICA and TPA. Ferritin proved the most sensitive marker with 73% positive results for tumours as opposed to 47.6% for CEA and GICA and only 19% for TPA. The division of tumours into histological types (Adenocarcinomas, squamous cell carcinomas, microcytomas and large cell anaplastic carcinomas) showed that Ferritin is the best marker for lung cancers (70% positive results in adenocarcinomas and squamous cell carcinomas, 62.5% in microcytomas, 87.5% in large cell anaplastic carcinomas). CEA and GICA display almost the same level of sensitivity in the different histological types: the sensitivity of TPA is low in all cases. Specificity was found to be satisfactory for all markers examined. It may be concluded that best results are obtained by combining Ferritin assay with CEA and/or GICA tests.

Adenocarcinoma↗